India is the world’s third-largest pharmaceutical producer by volume in 2026, but its export strength in generics and vaccines contrasts with continued dependence on imported APIs and intermediates.
India’s pharmaceutical industry has moved from heavy reliance on imported medicines after independence to supplying generics, vaccines and formulations across major global markets.
Western multinational companies controlled roughly 80–90% of India’s pharmaceutical market in 1947, while indigenous drug production was worth about ₹10 crore. By 2026, India ranked third globally in pharmaceutical production by volume and 11th by value.
The transformation was not a straightforward move to complete self-sufficiency. India built substantial strength in finished formulations, generic medicines and vaccines, while continuing to depend heavily on imported active pharmaceutical ingredients (APIs), bulk drugs and intermediates.
Building domestic capacity after independence
At independence, India’s pharmaceutical market depended heavily on foreign companies and imported medicines or raw materials. The government responded by investing in domestic manufacturing capacity.
Hindustan Antibiotics Limited (HAL) was established in 1954, with its plant commissioned in 1955–56 to manufacture antibiotics including penicillin and streptomycin. Indian Drugs and Pharmaceuticals Limited (IDPL) followed in 1961, with the objective of building self-reliance in essential and life-saving medicines.
Domestic output expanded from ₹10 crore in 1947 to ₹168 crore in 1965–66. By 1994–95, drug output had reached ₹9,453 crore. These are nominal historical figures rather than inflation-adjusted comparisons.
The 1970 Patent Act changes the industry
A central policy change came with the Patents Act, 1970, which took effect in 1972.
The earlier patent system allowed protection for pharmaceutical products and manufacturing processes. The 1970 law removed pharmaceutical product patents and provided limited-duration protection for processes.
Indian manufacturers could therefore produce medicines patented elsewhere if they developed alternative manufacturing processes. The system encouraged domestic companies to build expertise in reverse engineering, chemical synthesis and process chemistry.
Indian-owned firms accounted for about 15% of the domestic pharmaceutical market in 1970, according to the historical figures cited in the source. Their share increased to approximately 50% by 1982 and 61% by 1999.
A separate measure of domestic firms’ share of pharmaceutical production shows a similar shift, rising from 27% in 1975–76 to 52% in 1980–81.
Price controls accompany patent policy
Drug-price regulation also shaped the sector. The Drug Prices Control Order (DPCO), 1970 strengthened direct price regulation, while the Drug Policy of 1978 and DPCO 1979 extended controls to hundreds of bulk drugs and formulations.
The number of bulk drugs covered by price controls changed substantially over subsequent decades:
- DPCO 1970 initially covered 18, later 31.
- DPCO 1979 covered about 347–370.
- DPCO 1987 covered 142.
- DPCO 1995 covered 74.
- DPCO 2013 shifted to essential formulations based on the National List of Essential Medicines (NLEM).
The policies sought to combine domestic pharmaceutical production with affordable access to essential medicines, although the source notes that controls also created profitability and investment distortions in some segments.
Liberalisation opens global markets
Economic liberalisation after 1991 began another phase of the industry’s development. Industrial licensing restrictions were relaxed and trade barriers declined, while Indian drugmakers increasingly pursued overseas markets.
India joined the World Trade Organization in 1995, bringing the country under the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS. India was given until January 1, 2005, to introduce pharmaceutical product patents.
During this period, Indian companies expanded into regulated international markets. Their activities included filing Abbreviated New Drug Applications in the United States, securing USFDA and European regulatory approvals, buying foreign generic-drug businesses and expanding API and finished-formulation exports.
Pharmaceutical exports rose from approximately US$1.9 billion in 2000–01 to US$15.43 billion in 2014–15.
They reached US$30.47 billion in 2024–25 and about US$31.12 billion in 2025–26. Exports during April-July 2026 stood at US$10.78 billion, up 5.2% year on year.
Product patents return in 2005
India restored pharmaceutical product patents through the Patents (Amendment) Act, 2005, completing its transition to the TRIPS framework.
Indian companies could no longer produce newly patented medicines solely by developing an alternative manufacturing process.
The patent system retained public-health safeguards, including Section 3(d), which restricts patents on new forms of known substances unless they meet the required enhancement in efficacy. The provision was intended in part to prevent pharmaceutical patent “evergreening”.
Indian manufacturers subsequently competed through scale, process efficiency, regulatory compliance, research and development, complex generics and access to regulated global markets.
Generics underpin India’s global position
By 2026, India had more than 3,000 pharmaceutical companies and around 10,500 manufacturing units, while its domestic pharmaceutical market was estimated at about US$60 billion.
The country accounted for approximately 20% of global generic medicine supply, according to figures in the source.
Its reported share included:
- more than 50% of Africa’s generic medicine requirements;
- around 40% of generic demand in the United States;
- approximately 25% of medicines consumed in the UK; and
- more than 70% of global antiretroviral medicine supply, according to Department of Pharmaceuticals estimates.
These figures underpin India’s description as the “Pharmacy of the World”, particularly for lower-cost generic medicines.
Vaccine production extends India’s global role
India’s pharmaceutical manufacturing base also has a substantial vaccine component.
Indian manufacturers account for roughly 60% of vaccines supplied to UNICEF, according to the figures provided. Government estimates put their share at 40–70% of WHO demand for DPT and BCG vaccines and about 90% of WHO demand for measles vaccine.
The country’s vaccine and pharmaceutical manufacturing capacity became particularly visible during the COVID-19 pandemic.
Finished formulations dominate exports
India exported pharmaceuticals to 191 countries in FY2024–25, with about half of exports going to highly regulated markets including the United States and Europe.
Finished formulations and biological products accounted for most of the US$30.47 billion exported that year:
- Drugs formulations and biologicals: 75.26%
- Bulk drugs and intermediates: 15.98%
- Vaccines: 4.01%
- Surgical products: 2.48%
- AYUSH and herbal products: 2.26%
The United States accounted for about 34.5% of Indian pharmaceutical exports in FY2024–25.
Industry turnover reaches ₹4.72 lakh crore
India’s pharmaceutical industry recorded turnover of approximately ₹4,71,898 crore, or ₹4.72 lakh crore, in FY2024–25, according to the Department of Pharmaceuticals figures cited in the source.
Turnover rose from ₹3,28,054 crore in FY2020–21 to ₹3,44,125 crore in 2021–22, ₹3,79,450 crore in 2022–23 and ₹4,17,345 crore in 2023–24 before reaching the FY2024–25 figure.
The source puts the compound annual growth rate since FY2020–21 at about 9.5%.
API dependence remains a weak point
India’s position as a large exporter of finished medicines has not eliminated its dependence on imported pharmaceutical inputs.
In FY2024–25, the country imported approximately US$4.35 billion of APIs, bulk drugs and drug intermediates across 200 categories.
China supplied US$3.205 billion, or 73.71%, of those imports. The European Union accounted for 13.64%, followed by Singapore at 2.49%, the United States at 1.96% and Japan at 1.82%.
For several critical APIs, including certain antibiotics and pharmaceutical intermediates, dependence on Chinese imports remained at 90–100% in FY2024–25.
The figures expose a central contrast in the industry: India has developed large-scale global exports of finished pharmaceutical products while remaining dependent on overseas suppliers for some of the ingredients used to make them.
PLI schemes target domestic input production
Supply disruptions during the COVID-19 pandemic brought greater attention to API supply chains. The government subsequently used Production Linked Incentive (PLI) programmes for pharmaceuticals, bulk drugs and related inputs to expand domestic manufacturing.
By March 2026, the main PLI Scheme for Pharmaceuticals had attracted cumulative investment of ₹45,774 crore and contributed to employment for about 116,884 people, according to the government figures cited.
The bulk-drug programme had created annual capacity of roughly 56,800 metric tonnes for 28 of 41 identified critical products by March 2026.
Government estimates published that month said PLI interventions had helped avoid about ₹3,591 crore of imports of APIs, key starting materials and drug intermediates.
Policy turns towards biologics and innovation
The industry’s next phase is increasingly focused on higher-value pharmaceutical manufacturing and research, including biologics, biosimilars, complex generics, novel drug delivery, cell and gene therapies, precision medicine, vaccines and contract research and development.
The Biopharma SHAKTI initiative announced for 2026–27 proposed ₹10,000 crore over five years.
Plans include three new National Institutes of Pharmaceutical Education and Research, upgrades to seven existing NIPERs and a network of more than 1,000 accredited clinical-trial sites.
The proposed direction would extend India’s pharmaceutical strategy beyond affordable generic production towards domestic development and manufacturing of more complex and higher-value medicines.
India’s pharmaceutical journey, 1947–2026
The industry’s development can be traced through several policy and manufacturing turning points:
- 1947: Western multinationals hold 80–90% of the market; indigenous production stands at ₹10 crore.
- 1954–61: HAL and IDPL are established to expand domestic pharmaceutical manufacturing.
- 1970: The Patents Act changes the patent framework for pharmaceuticals.
- 1972: The Act comes into force, allowing process rather than product patents for medicines.
- 1978–79: Drug policy and price controls focus on self-reliance, essential medicines and affordability.
- 1991: Economic liberalisation begins.
- 1995: India enters the WTO/TRIPS framework.
- 1997: The National Pharmaceutical Pricing Authority is established.
- 2000–01: Pharmaceutical exports stand at approximately US$1.9 billion.
- 2005: India restores pharmaceutical product patents.
- 2014–15: Exports reach US$15.43 billion.
- 2020: The pandemic highlights both India’s vaccine and formulation capacity and its dependence on imported pharmaceutical inputs.
- 2020 onward: PLI programmes seek to expand bulk-drug and pharmaceutical manufacturing.
- 2024–25: Industry turnover reaches ₹4.72 lakh crore and exports reach US$30.47 billion.
- 2025–26: Exports rise to approximately US$31.12 billion.
- 2026: India ranks third globally in pharmaceutical production by volume and 11th by value, while policy increasingly targets APIs, biologics, biosimilars and pharmaceutical innovation.
India’s 79-year pharmaceutical transformation has therefore produced two distinct outcomes. The country has developed a large domestic industry and a global position in generic medicines, formulations and vaccines, but remains dependent on imported APIs and intermediates for parts of its supply chain.
That dependence has put upstream manufacturing alongside biologics and pharmaceutical research at the centre of the industry’s next phase.
TL;DR:
India moved from an import-dependent pharmaceutical market in 1947 to the world’s third-largest producer by volume in 2026. Exports exceed US$31 billion, but dependence on imported APIs, particularly from China, remains a major supply-chain issue.
AI summary:
- Western multinationals controlled roughly 80–90% of India’s pharmaceutical market at independence.
- The Patents Act, 1970 helped domestic companies develop generic manufacturing and process-chemistry capabilities.
- Pharmaceutical exports increased from about US$1.9 billion in 2000–01 to roughly US$31.12 billion in 2025–26.
- India supplies about 20% of global generics, while China accounted for 73.71% of specified API, bulk-drug and intermediate imports in FY2024–25.
- PLI programmes and Biopharma SHAKTI are targeting domestic inputs, biologics and higher-value pharmaceutical development.
Disclaimer : Opinions and investment insights shared by experts are personal and independent. Management assume no responsibility for investment decisions made based on such views. Investors should seek guidance from qualified financial professionals prior to acting.
